Andere Sprachen Sana Biotechnology, Inc.

Aktien

A2QNUE

US7995661045

SANA

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:31:22 02.05.2024			% 5 Tage	% 1. Jan.
9,42 ^USD	-2,18 %		+11,76 %	+132,84 %

18.04.	Sana Biotechnology, Inc. gibt den Rücktritt von Douglas Williams als Executive Vice President und Präsident für Forschung und Entwicklung bekannt	CI
01.03.	SANA BIOTECHNOLOGY, INC. : Bewertung von JMP Securities kaufen	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sana Biotechnology, Inc. Announces Resignation of Douglas Williams as Executive Vice President and President, Research and Development	18.04.
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09.04.
Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	09.04.
Certain Stock Options of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	09.04.
Certain Common Stock of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	09.04.
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows	01.03.
Sector Update: Health Care Stocks Edge Higher Premarket Friday	01.03.
Sana Biotechnology Q4 Non-GAAP Net Loss Narrows; Cash, Cash Equivalents Decline	29.02.
Sana: Q4 Earnings Snapshot	29.02.
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	29.02.
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference	28.02.
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	16.02.
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP	13.02.
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP	13.02.
Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP	13.02.
Breaking Ground in BioPharma: Spotlight Companies DYAI, INBS, SANA, IOVA, BLUE	13.02.
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing	12.02.
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing	12.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Sana Biotechnology, Inc.

Aktien

A2QNUE

US7995661045

SANA

Andere Sprachen

Filter